MICARDIS is an angiotensin II receptor blocker (ARB) indicated for:
• Treatment of hypertension
• Cardiovascular (CV) risk reduction in patients unable to take ACEinhibitors

• Hypertension: The most common adverse events (≥1%) reported in hypertension trials are back pain, sinusitis, and diarrhea
• Cardiovascular risk reduction: The serious adverse events (≥1%) reported in cardiovascular risk reduction trials were intermittent claudication and skin ulcer

• NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect

• Avoid fetal or neonatal exposure
• Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension
• Monitor carefully in patients with impaired hepatic or renal function
• Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker